Vitrectomy for Branch Retinal Vein Occlusion

Vitrectomy for Persistent Macular Edema in Branch Retinal Vein Occlusion

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00685490

Enrollment

Registered

2008-05-28

Start date

1995-07-31

Completion date

2006-11-30

Last updated

2008-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitrectomy

Keywords

branch retinal vein occlusion, internal limiting membrane, macular edema, vitrectomy

Brief summary

To evaluate the long term outcomes of pars plana vitrectomy (PPV), with and without internal limiting membrane (ILM) peeling, in eyes with persistent macular edema secondary to branch retinal vein occlusion (BRVO). Results suggest the following hypothesis: * PPV, with and without ILM peeling, appears to be beneficial in eyes with persistent macular edema due to BRVO * Effectiveness is maintained long term * ILM peeling does not significantly affect postoperative best corrected visual acuity (BCVA)

Interventions

PROCEDUREVitrectomy w/o ILM peeling for macular edema with BRVO

Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

45 Years to 86 Years

Healthy volunteers

Inclusion criteria

* duration of symptoms lasting 27 weeks

Exclusion criteria

* vitreous hemorrhage * severe cataract * biomicroscopic vitreomacular traction and epiretinal membrane * previous vitreoretinal surgery * other ocular diseases that could contribute to visual loss. * patients with macular branch vein occlusion * patients with a history of previous grid laser photocoagulation

Design outcomes

Primary

Measure	Time frame
Reporting of the long term outcomes of PPV, with and without ILM peeling, in eyes with persistent macular edema secondary to BRVO	11 years

Secondary

Measure	Time frame
Elevate the effectiveness of ILM peeling	11 years

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026